anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Animal studies modeling recreational opioid use show more severe withdrawal symptoms in male compared to female rats, whereas our study modeling opioid use for pain showed a greater withdrawal-induced decrease in wheel running in female rats. The objective of this experiment was to determine whether sex differences in spontaneous morphine withdrawal are caused by differences in assessment method (i.e., wheel running vs. somatic symptoms). Twice daily injections of morphine (5 - 20 mg/kg, s.c.) for 5 days produced a dose and time dependent decrease in wheel running that was greater in male compared to female rats. Termination of morphine administration resulted in an overall decrease in running and a decrease in the amount of running during the dark phase of the light cycle from 95 % to approximately 75 %. In male rats, this decrease in the percent of dark running was caused by a large decrease in dark phase running, whereas female rats had a slightly higher increase in light phase running. Withdrawal also reduced maximal running speed and caused a decrease in body weight that was larger in male than female rats. Withdrawal symptoms were greatest on the day following the last morphine injection, but persisted for all 3 days of assessment. Morphine withdrawal produced a greater decrease in dark phase wheel running and body weight in male rats and a greater increase in light phase running in female rats. Voluntary home cage wheel running provides a continuous measure of opioid withdrawal that is consistent with other measures of opioid withdrawal.
PURPOSE: A manufacturing method of amyloid using ionic liquid is provided to show that the ionic liquid having the structure of Chemical formula 1 induces and accelerates protein to form amyloid, and to be able to shorten the amyloid manufacture to one week or less. CONSTITUTION: A manufacturing method of amyloid using ionic liquid comprises a step of incubating with treatment of protein with an ionic liquid compound (a compound with 1-butyl-3-methyl imidazolium as cation, in Chemical formula 1, X represents an anionic compound) represented by Chemical formula 1. The cationic compound is selected from the group consisting of bis (trifluoromethylsulfonyl)imide, tetrafluoro borate, hexafluoro phosphate, and methylsulfonate. The incubation is performed for 2-8 days. The protein is any one among hen egg white lysozyme (HEWL), calcium-saturated alpha-lactalbumin, trypsin, and insulin. A composition for biomaterial includes amyloid manufactured by said manufacturing method.
29,842. Dodd, W. R. Dec. 29. Suppositories.-A suppository comprises an enlarged bead a and a tapering body portion b. A suitable material consists of a mixture of cacao butter with five per cent of wax. This material may be employed for the whole suppository, or may form the body portion only, a material such as vulcanite being used for the head. According to the Provisional Specification, a tape may be attached to the suppository to'keep it in position or to assist in its withdrawal.
The invention discloses a kadsurae caulis ethanol extract and a high-extraction-rate preparation method thereof. The extract comprises total lignans with the content not smaller than 2.75%. The preparation method comprises steps as follows: a pretreatment step: after impurities in the medicinal material, namely, kadsurae caulis are cleared preliminarily, kadsurae caulis is sliced, crushed and sieved, throughs are reserved, and kadsurae caulis powder is obtained; an extraction step: the kadsurae caulis powder is soaked in 70%-85% ethanol for 20-36 h and percolated at the speed of 1-3 volume multiples/h, and a percolating liquid in the volume of 40-50 times is collected; a separation step: the percolating liquid is concentrated under reduced pressure or concentrated by a rotary evaporimeter until no ethanol smell, ethanol is recovered, and the kadsurae caulis ethanol extract is obtained. The extraction rate and the content of the total lignans are 6.9 times and 10.5 times those with a water decoction method respectively. The extract has good dissolubility, is easy to crush and has good quality stability. The preparation method has the characteristics that the extraction rate of total lignans is high, the extract contains few impurities and the process is simple and economical.
Patients receive health-related information for 8 weeks on study. Patients are then offered a session of supervised exercise followed by 7 weeks of tele-coaching sessions. Patients also undergo collection of blood samples at baseline and week 8.
With the innovations of laparoscopic technique and specialized equipment , laparoscopic liver resection became the dominating resection surgery approach. December of 2014, laparoscopic hepatectomy was carried out in our department, extracorporeal Pringle maneuver has been applied in most laparoscopic liver resections which need to block the hepatic inflow, cotton tape was the frequently used tourniquet. We used to blocked the hepatic inflow by extracorporeal Pringle maneuver method with cotton tape for its validity , softness and no visible damages for vessel, but it was always difficult for clamping in a two-dimensional view to encircle the hepatoduodenal ligament , and it delayed operation time for freshmen. Bulldog has been widely used in urinary surgery for vascular occlusion, but bulldog in hepatic surgery has rarely been mentioned, this is the first report to formally demonstrate the clinical application in hepatic surgery. However, it is not clear that whether the bulldog for vascular occlusion is useful and easy to implement in laparoscopic hepatectomy. In this study, we will compare the cotton and the bulldog for vascular occlusion during laparoscopic hepatectomy
Anemia is commonly present in patients with end-stage renal failure (ESRF) due to insufficient endogenous erythropoietin production, absolute and functional iron deficiency. With the introduction of recombinant human erythropoietin (rHuEPO) and the accessibility of rHuEPO to dialysis patients in the Hospital Authority Drug Formulary, blood transfusion requirement for the treatment of renal related anemia has been much reduced. However, iron store must also be adequately maintained for effective erythropoiesis. The latest KDIGO guideline for anemia in chronic kidney disease recommends iron therapy either in oral or intravenous form if TSAT is ≤30% and ferritin is ≤500µg/L. Oral iron supplement is the most convenient, but it is less effective compared to intravenous forms, especially in the treatment of functional iron deficiency, and has unfavorable patient tolerability and gastro-intestinal side-effect profiles. Iron sucrose (Venofer®) is the most widely used intravenous iron preparation with good safety profile. An initial course of intravenous iron (e.g. Venofer® 200mg weekly for 5 weeks) is commonly given to iron-deplete patients before consideration of maintenance iron therapy. The absence of a vascular access and the need to return to hospital facilities for regular intravenous infusions made intravenous forms less preferred by patients on peritoneal dialysis (PD). Isomaltoside 1000 (Monofer®) consists of iron with a tighter binding to its carbohydrate moiety with less free iron to cause immunologic reactions, and thus allowing for a larger single-dose administration. This may facilitate better acceptance of intravenous iron by patients on PD. The current literature on the efficacy and safety profile of Monofer® in the treatment of renal-related anemia focus mainly on patients on hemodialysis and patients with non-dialysis dependent chronic kidney disease. There is also a lack of information on patient-reported satisfaction on the use of Monofer®. The objective of the current study is to investigate patient-reported satisfaction, efficacy and short-term safety profile of a single bolus of Monofer® compared to Venofer® in the treatment of both absolute and functional iron deficiency anemia in patients on PD. In the second part of the study, patients with recurrent iron deficiency will be crossed-over to receive treatment of the alternative arm. Similar to the first part of the study, patient-reported satisfaction and treatment efficacy will be compared following the same study protocol.
For the treatment group, a total of 100 milliliters (mLs) of acetaminophen (1000 mg) will be transferred to a Hospira LifeCare container and infused over 15 minutes (6.7 mLs/min). A beyond use expiration of 6 hours at room temperature will place on the container, as recommended by the manufacturer.
Injectable medicament formulations comprise a water/oil emulsion suspended in a biologically acceptable aq. soln. The vol. ratio of the soln. phase to the emulsion phase is >=1:2. The external phase of the emulsion comprises an oil which will be transported through the body, and an oil-sol. surfactant. The internal phase comprises a medicament which will be released into the body fluids over a predetermined period of time. The formulations have a lower viscosity than conventional emulsions; injections are thus less painful.
Glasdegib will be self-administered orally once daily in the morning as monotherapy in continuous 28-day treatment cycles for a maximum of 24 cycles. Those patients enrolled in the trial that obtain objective clinical benefit under treatment with glasdegib (defined as the achievement of at least a partial response at one or more target organs), will be allowed to proceed to a slow dose withdrawal phase over a period of 6 months after the end of Cycle 24. The dose reduction scheme is fully detailed in the protocol.
In certain embodiments, trigger-associated user messaging may be facilitated. In some embodiments, a first set of candidate users for messaging with a first user in connection with occurrence of a first trigger associated with the first user may be obtained. The first user may be monitored via one or more sensors for occurrence of the first trigger. A first occurrence of the first trigger may be determined based on the monitoring. Based on the first occurrence of the first trigger, the first set of candidate users may be accessed to initiate messaging between the first user and one or more users of the first set of candidate users. Messaging between the first user and a second user (of the first set of candidate users) may be initiated based on the second user having a higher priority than a third user of the first set of candidate users.
PROBLEM TO BE SOLVED: To obtain a gelled composition having good spreadability during coating and excellent feeling in use and excellent in time dependent preservation stability by combining predetermined amount of a specific copolymer, a specific nonionic surfactant and a liquid oil. SOLUTION: This gelled composition is obtained by blending (A) a copolymer obtained from a monomer comprising 1-50wt.% long chain alkyl acrylate monomer of the formula (R is a 10-30C alkyl; R' is H or methyl) and 99-50wt.% olefinic unsaturated carboxylic and monomer, (B) a nonionic surfactant having HLB >=10 and (C) 40-85wt.% liquid oil based on the final composition. As the monomer of the formula, e.g. decyl acrylate, lauryl acrylate, etc., can be cited. As the ingredient (B), e.g. polyoxyethylene alkyl ether, etc., can be cited and is blended in about 1.0-30.0wt.% to the composition. As the ingredient (C), liquid paraffin, etc., can be cited.
In Phase I, there will be 9 to 18 patients enrolled. Cohorts of 3 to 6 patients will receive escalated dose of cisplatin and fluorouracil until the MTD is reached. There will be no intra-patient dose escalation. Sorafenib will be administered orally at a dose of 400mg bid for 28 days in the all patients. Cisplatin at the dose of 10-20mg/m2 will be administered at day 1 and day8, and fluorouracil at the dose of 170-330mg/m2 will be administered continuously at day1-day5, and day8-day12 via the implanted catheter system. A cycle is defined as 28 days and 3 cycles of this combination therapy will be continued. At the end of each cycle, adverse effect will be evaluated and dose escalation will be determined. In Phase II, there will be 28 patients enrolled. Time to progression of this combination therapy at the recommended dose will be evaluated.
In order to generate annotated ground truth data for training a machine learning model for inferring a desired scan configuration of an medical imaging system from an observed workflow scene during exam preparation, a system is provided that comprises a sensor data interface configured to access a measurement image of a patient positioned for an imaging examination. The measurement image is generated on the basis of sensor data obtained from a sensor arrangement, which has a field of view including at least part of an area, where the patient is positioned for imaging. The system further comprises a medical image data interface configured to access a medical image of the patient obtained from a medical imaging apparatus during the imaging examination. The patient is positioned in a given geometry with respect to a reference coordinate system of the medical imaging apparatus. The system further comprises an exam metadata interface configured to access exam metadata of the imaging examination. The system further comprises a processing unit, configured to determine an association between one or more features in the measurement image and one or more features extracted from the medical image and/or from the exam metadata by mapping a point in a coordinate system of the medical image to a point in a coordinate system of the measurement image. The system further comprises an output interface, configured to be coupled to a training set database for adding the measurement image comprising data that labels the one or more associated features in the measurement image to the training set database for training the machine learning model.
FIELD: medicine, gastroenterology, pharmacy. SUBSTANCE: invention relates to S-omeprasol in neutral form that is efficient as an inhibitor of secretion of gastric acid and useful as an antiulcer agent. Invention describes S-omeprasol in neutral form existing in an essentially crystalline form. Invention discloses also methods of preparing S-omeprasol in neutral form A and in neutral form B, a pharmaceutical composition comprising S-omeprasol in neutral form and a method of treatment of a state associated with gastric acid. EFFECT: higher efficiency. 17 cl, 2 dwg, 1 tbl
INTRODUCTION: Primary graft dysfunction (PGD) is a known risk factor for early mortality following lung transplant (LT). However, the outcomes of patients who achieve long-term survival following index hospitalization are unknown. We aimed to determine the long-term association of PGD grade 3 (PGD3) in patients without in-hospital mortality.
METHODS: LT recipients were identified from the United Network for Organ Sharing Database. Patients were stratified based on the grade of PGD at 72 h (No PGD, Grade 1/2 or Grade 3). Groups were assessed with comparative statistics. Long-term survival was evaluated using Kaplan-Meier methods and a multivariable shared frailty model including recipient, donor, and transplant characteristics.
RESULTS: The PGD3 group had significantly increased length of stay, dialysis, and treated rejection post-transplant (P < 0.001). Unadjusted survival analysis revealed a significant difference in long-term survival (P < 0.001) between groups; however, following adjustment, PGD3 was not independently associated with long-term survival (hazard ratio: 0.972; 95% confidence interval: 0.862-1.096). Increased mortality was significantly associated with increased recipient age and treated rejection. Decreased mortality was significantly associated with no donor diabetes, bilateral LT as compared to single LT, transplant in 2015-2016 and 2017-2018, and no post-transplant dialysis.
CONCLUSIONS: While PGD3 remains a challenge post LT, PGD3 at 72 h is not independently associated with decreased long-term survival, while complications such as dialysis and rejection are, in patients who survive index hospitalization. Transplant providers should be aggressive in preventing further complications in recipients with severe PGD to minimize the negative association on long-term survival.
The invention discloses a macromolecular phosphatidylglycerol nanoliposome, and preparation methods and applications thereof, and belongs to liposome preparation and application technologies. The phosphatidylglycerol nanoliposome is vesicles having a bilayer lipid membrane structure prepared by using phosphatidylglycerol chitosan to substitute phosphatide as a primary membrane material. The phosphatidylglycerol chitosan has a weight average molecular weight of above 2000, can be dissolved in organic solvents comprising chloroform, ethanol and the like, and contains a carboxyl or amino group. The preparation methods of the nanoliposome adopt common liposome preparation methods comprising a membrane dispersion method and an inverted evaporation method. The surface of like liposomes can be connected with a plurality of targeting preparations, and can simultaneously and respectively entrap water-soluble, oil-soluble or amphiphilic substances comprising medicines, proteins, genes, nutrients, vitamins, magnetic particles, quantum dots and the like. The methods have the advantages of high entrapment rate, simple operation, strong applicability and low cost, and the dressed macromolecular liposome has the advantages of uniform particle size distribution, adjustability in a range of 10-5000nm, stable system and strong slow release function.
Maternal prenatal stress and anxiety can affect brain development in fetuses with and without congenital heart disease (CHD), influencing neurodevelopmental trajectories and establishing a neural basis for phenotypes associated with adverse mental health outcomes later in life. The prenatal period offers a critical window of opportunity, when ameliorating maternal psychological stress is likely to have enormous benefits for parents and their babies. Yet, there is a remarkable lack of prenatal interventions to support parent mental health and optimize child development during this period. This longitudinal randomized controlled trial compares a novel, 8-week, prenatally-delivered psychological intervention (called HeartGPS) to usual fetal cardiac care. In comparison with usual care, the study aims are to examine the effects of HeartGPS on: (1) maternal psychological distress (anxiety, depression, and traumatic stress) across the perinatal period; (2) fetal and infant brain development; (3) infant neurodevelopment; and (4) parent-infant behavioral synchrony. The study will also explore how neurobiological, psychological, behavioral, and social factors may explain intervention effects.

Across multiple sites, the investigators will enroll 104 mothers and their babies with single ventricle congenital heart disease to receive usual fetal cardiac care or usual fetal cardiac care plus the HeartGPS intervention. HeartGPS includes psychology sessions during pregnancy and the early postpartum period, coupled with tailored educational resources, and a personalized care plan to support longer-term parent, child, and family mental health and wellbeing. Maternal prenatal assessments will be performed at baseline (pre-randomization) and approximately 36-weeks gestation followed by maternal and infant assessments at approximately infant age 28-days, 6-months, and 12-months. Fetal neuroimaging will occur at approximately 36-weeks gestation and infant neuroimaging will take place at approximately infant age 28-days, using structural and functional magnetic resonance imaging (MRI). Placental tissue, maternal, paternal and infant blood, and maternal and infant saliva samples will also be collected. The primary outcomes for the trial are changes in maternal anxiety, depression, and traumatic stress scores from baseline to 6-months postpartum. Secondary outcomes include neonatal neurobehavior (NeoNatal Neurobehavioral Scale), infant neurodevelopment at 12 months (Bayley Scales of Infant Development), and mother-infant behavioral synchrony at 12 months (CARE-Index). In addition to rigorously testing a promising new therapy, this study will generate knowledge to accelerate treatments for maternal prenatal psychological stress and define mechanisms underlying the fetal origins of brain development and neurodevelopmental outcomes in CHD.
A method and system for providing physical therapy to a human client having a physical condition includes the steps of providing an electronic communication link between the client and a therapist, instructing the client to move in a particular manner, or to assume a sustained posture or perform a test. Then, feedback is requested from the client. The feedback relates to bodily sensation corresponding to the movement or sustained posture and can be audio, video, and/or data type feedback. The communication link communicates the feedback to the therapist. Accordingly, the therapist utilizes the feedback to assess the physical condition of the client. The therapist also communicates remedial movements or a remedial sustained posture to the client to address the physical condition. Various postural measurements and testing devices are be used in conjunction with the present invention to facilitate assessment and help address the physical condition in accordance with accepted physical therapy techniques.
The rehabilitation program will be an active exercise based on the available literature and considers the clinical experience in managing groin injuries. An experienced physical therapist will supervise the rehabilitation program for two sessions weekly for eight weeks, with difficulty and volume progressing incrementally. Sessions will last between 30 and 120 minutes.
SHAM tDCS: Subjects will receive a total of 10 consecutive sessions of sham tDCS over a two-week period (administered Mon-Fri). During each session, the anode will be placed over the primary motor cortex of the predominantly painful side.
The present invention relates to a base powder for preparing functional beverages, soft drinks or an additive for food products, which is made with red raspberry from Rubus idaeus and with clinoptilolite zeolite contained in the ZAM® (activated micronized zeolite). The powder is prepared with dehydrated fruit juice. The raspberry juice extract is obtained by slowly heating (without exceeding 70°C) a pot containing the ground fruit or a receptacle with fruit, using the bain-marie method, without exceeding 70°C. The juice is stabilized, dehydrated optionally mixed with sugar substitutes, sweeteners or fiber, and, lastly, homogenized. The object of the present invention is to provide a food-grade base powder of natural origin that is totally different from current presentations of red raspberry on the market. Likewise, the present invention seeks to utilize the therapeutic properties of said fruit as a coadjuvant in controlling active and passive tobacco consumption, nicotine detoxification and nicotine addiction, and also detoxification in the case of other toxic substances in tobacco smoke, as an antioxidant, antimutagenic, anticancer agent and immunostimulant. It is 100% rehydratable in water, easy to transport and has a shelf life in excess of one year.
Experimental: Nordic walking Training The total period of training was composed by 9-week of walking with poles, two sessions per week. The cycles were divided into four microcycles composed of three training sessions. Each training session took 60 min. Nordic walking aerobics training was used during the training period. These exercises were performed alternating volume and intensity. The training session was divided into three stages: (a) stretching, joint mobility, and heating; (b) main part (NW); (c) return to the calm and ultimate stretching.